AcelRx Pharmaceuticals is in the medical devices industry and healthcare sector. The company CEO is Vincent J. Angotti. AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development and commercialization of therapies for the treatment of acute pain.
Previous Intraday Performance:
The ACRX shares had a previous change of -2.14% which opened at 2.81 and closed at 2.74. It moved to an intraday high of 2.86 and a low of 2.71.
SeekingAlpha: After Years Of Development, AcelRx’s Dsuvia Has Finally Generated Revenue
Historical Performance:
Over the last five trading days, ACRX shares returned -4.20% and in the past 30 trading days it returned -19.17%. Over three months, it changed -19.65%. In one year it has changed -5.52% and within that year its 52 week high was 5.05 and its 52 week low was 1.99. ACRX stock is 37.69% above its 52 week low.
Our calculations result in a 200 day moving average of 3.22 and a 50 day moving average of 3.35. Right now, ACRX stock is trading -14.86% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: After Years Of Development, AcelRx’s Dsuvia Has Finally Generated Revenue
Liquidity:
The company has a market cap of $216.2m with 78.9m shares outstanding and a float of 77.0m shares. Trading volume was 899,690 shares and has experienced an average volume of 1,745,961 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for AcelRx Pharmaceuticals was -0.81 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.23.
Below was the last reported quarterly diluted earnings per share:
1st | Qtr 2019 | -0.17 |
---|---|---|
4th | Qtr 2018 | -0.18 |
3rd | Qtr 2018 | -0.21 |
2nd | Qtr 2018 | -0.20 |
1st | Qtr 2018 | -0.23 |
Base on our calculations, the intrinsic value per share is 53.76, which means it might be undervalued and has a margin of safety of 94.90%.
The long-term trend of the EPS is an important number as it indicates the present value of AcelRx Pharmaceuticals; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -69.90% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 24.70% of institutional ownership.
The beta was calculated to be 2.35.
SeekingAlpha: Axcelis Technologies, Inc. (ACLS) CEO Mary Puma on Q1 2019 Results – Earnings Call Transcript
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is 194.62%, return on assets is -56.79%, price-to-sales is 106.59 and price-to-book is 61.42.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
3 : Financial Safety Result
0 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: AcelRx Pharmaceuticals, ACRX, Healthcare, Medical Devices